EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Extensive-stage small cell lung cancer in Hungary: a real-world analysis (2013–2022)

Krisztina Bogos, András Bajcsay, Gabriella Gálffy, Lilla Tamási, Zsolt Pápai-Székely, Veronika Sárosi, Anikó Maráz, Regina Pálföldi, Lilla Horváth, Judit Hoffer, Szilvia Szécsényi, Kata Kirschner und 6 weitere

Pathology & Oncology Research · 16.07.2026 · 32

DOI: 10.3389/pore.2026.1612491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology & Oncology Research, online erschienen am 16.07.2026. Verfasst von Krisztina Bogos und 17 weiteren Autor:innen. Beteiligte Einrichtung: National Korányi Institute of Pulmonology, Budapest, Hungary. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study provides a comprehensive nationwide analysis of extensive-stage small cell lung cancer (ES-SCLC) in Hungary, examining incidence rates, demographic trends, treatment patterns, and survival outcomes. We used data from the National Health Insurance Fund (NHIF) covering the period of 2013–2022, and we analyzed 8,104 ES-SCLC patients who received first-line (1L) etoposide-platinum (EP) chemotherapy, all of whom were confirmed to not have received concomitant chemoradiotherapy or curative thoracic surgery and had histology results in line with SCLC. We evaluated epidemiology, regional distribution, radiotherapy use, and subsequent treatment pathways. For the efficacy analysis, we narrowed the cohort to 5,576 patients who initiated EP within 1 year of their first C34-coded lung cancer diagnosis between 2013 and 2019, enabling 3-year follow-up. Key endpoints included overall survival (OS) and progression-free survival (PFS), the latter of which was inferred using time to first subsequent therapy (TFST). Our results revealed a shifting age distribution toward the age group above 70 years, while the male-to-female ratio gradually evened out. Treatment patterns showed the increasing use of carboplatin over cisplatin and frequent short course radiotherapy. Among those who underwent subsequent therapy, EP rechallenge was most widespread. Despite high initial response rates, survival outcomes remained poor: median PFS was 6.5 months (6-month: 52.9%, 1-year: 19%, 3-year: 5.2%), and median OS was 9.3 months (6-month: 69.8%, 1-year: 37.5%, 3-year: 9.2%). These results were in line with international real-world evidence and clinical trial data. Our findings highlight the aggressive nature of ES-SCLC and provide insight to the limited efficacy of chemotherapy-based therapies, underscoring the need to improve existing 1L and subsequent-line treatments and to introduce novel options. As Hungary transitions into the immunotherapy era, future studies with extended follow-up that incorporate staging, radiotherapy intent, comorbidities, and progression data will be essential for optimizing therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSmall Cell Lung CarcinomaAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleHungaryAgedMiddle AgedSurvival RateEtoposideCisplatinIncidenceAdultNeoplasm StagingAged, 80 and over

Stichwörter der Autor:innen

epidemiologyetoposide-platinumextensive-stageoverall survivalsmall cell lung cancer (SCLC)

Substanzen

EtoposideCisplatin

Autor:innen und Institutionen

  • National Korányi Institute of Pulmonology, Budapest, Hungary.
  • Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
  • Pulmonology Center of the Reformed Church in Hungary, Törökbálint, Hungary.
  • Károli Gáspár University of the Reformed Church in Hungary, Budapest, Hungary.
  • Department of Pulmonology, Semmelweis University, Budapest, Hungary.
  • Fejér County Szent György University Teaching Hospital, Székesfehérvár, Hungary.

Zitieren

APA

Bogos, K., Bajcsay, A., Gálffy, G., Tamási, L., Pápai-Székely, Z., Sárosi, V., Maráz, A., Pálföldi, R., Horváth, L., Hoffer, J., Szécsényi, S., Kirschner, K., Blasszauer, C., Reibl, D., Komka, I., Ascsillán, A. A., Kemény, L. V., & Ostoros, G. (2026). Extensive-stage small cell lung cancer in Hungary: a real-world analysis (2013–2022). Pathology & Oncology Research, 32. https://doi.org/10.3389/pore.2026.1612491

Vancouver

Bogos K, Bajcsay A, Gálffy G, Tamási L, Pápai-Székely Z, Sárosi V, et al. Extensive-stage small cell lung cancer in Hungary: a real-world analysis (2013–2022). Pathology & Oncology Research. 2026;32. doi:10.3389/pore.2026.1612491

BibTeX
@article{Bogos2026,
  author = {Bogos, Krisztina and Bajcsay, András and Gálffy, Gabriella and Tamási, Lilla and Pápai-Székely, Zsolt and Sárosi, Veronika and Maráz, Anikó and Pálföldi, Regina and Horváth, Lilla and Hoffer, Judit and Szécsényi, Szilvia and Kirschner, Kata and Blasszauer, Celia and Reibl, Dániel and Komka, Ida and Ascsillán, Anna A and Kemény, Lajos V and Ostoros, Gyula},
  title = {Extensive-stage small cell lung cancer in Hungary: a real-world analysis (2013–2022)},
  journal = {Pathology & Oncology Research},
  year = {2026},
  volume = {32},
  doi = {10.3389/pore.2026.1612491}
}
Kostenlos starten →